|
시장보고서
상품코드
2091541
오믹스 기반 임상시험 시장 규모, 점유율, 성장 분석 : 오믹스 종류별, 서비스 종류별, 단계별, 용도별, 기술별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Omics-Based Clinical Trials Market Size, Share, and Growth Analysis, By Omics Type (Genomics, Proteomics), By Service Type, By Phase, By Application, By Technology, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 오믹스 기반 임상시험 시장 규모는 2024년에 87억 달러로 평가되었으며, 2025년 98억 1,000만 달러에서 2033년까지 257억 2,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 12.8%로 성장할 것으로 전망됩니다.
세계 오믹스 기반 임상시험 시장은 정밀 의학에 대한 수요 증가를 원동력으로 삼아 눈부신 성장을 이루고 있습니다. 이러한 접근 방식을 통해 분자적 특징에 기반한 환자 분류가 가능해지며, 기존 방법에 비해 임상시험의 유효성이 향상됩니다. 차세대 염기서열 분석 등의 기술 발전으로 분석 능력이 확대되고, 특정 분야에 집중한 연구가 가능해짐에 따라 성공률이 향상될 뿐만 아니라, 표본 규모와 소요 기간도 단축되고 있습니다. 규제 체계 또한 바이오마커 중심 연구를 점점 더 뒷받침하고 있으며, 다수의 변이를 동시에 평가할 수 있는 다중 패널의 활용이 촉진되고 있습니다. 이러한 발전은 단일 세포 RNA 시퀀싱 등의 기술과 결합되어 임상시험 과정을 효율화하고, 비용을 절감하며, 투자를 유치하고 있습니다. 그 결과, 제약 기업들은 이러한 이점을 활용하여 혁신의 선순환과 새로운 치료법의 신속한 개발을 촉진하고 있습니다.
세계 오믹스 기반 임상시험 시장의 성장요인
세계 오믹스 기반 임상시험 시장의 주요 성장 촉진요인 중 하나는 개인의 유전적, 단백질체학적 또는 대사 프로파일에 따라 치료법을 최적화하는 ‘맞춤형 의료’에 대한 수요가 증가하고 있다는 점입니다. 게노믹스, 단백질체학, 대사체학과 같은 오믹스 기술의 발전 덕분에 연구자들은 복잡한 생물학적 과정을 이해하고, 치료법의 유효성과 안전성을 높일 수 있는 바이오마커를 규명할 수 있게 되었습니다. 또한, 만성 질환 유병률의 증가와 보다 정밀하게 표적을 겨냥한 치료 접근법에 대한 수요 증가가 오믹스 연구에 대한 투자를 촉진하고 있습니다. 그 결과, 제약 회사와 생명공학 기업들은 신약 개발 과정을 효율화하고 환자의 예후를 개선하기 위해 오믹스 기반의 연구 기법을 점점 더 많이 도입하고 있습니다.
세계 오믹스 기반 임상시험 시장의 제약요인
세계 오믹스 기반 임상시험 시장의 주요 제약요인 중 하나는 오믹스 기술을 기존의 임상시험 체계에 통합하는 데 따르는 높은 비용과 복잡성입니다. 게노믹스, 단백질체학, 대사체학 등 이러한 첨단 기술을 도입하려면 전용 장비, 숙련된 인력, 그리고 데이터 분석 및 관리 시스템에 대한 막대한 투자가 필요합니다. 이러한 복잡성은 시험 기간의 장기화와 운영 비용의 증가로 이어지며, 소규모 조직이 이러한 연구에 참여하는 것을 주저하게 만드는 요인이 됩니다. 또한, 규제상의 과제와 오믹스 데이터의 표준화 필요성도 시장 내 광범위한 보급과 성장의 걸림돌이 될 수 있습니다.
세계 오믹스 기반 임상시험 시장의 동향
세계 오믹스 기반 임상시험 시장에서는 오믹스 기술의 발전에 힘입어 정밀 의학과의 통합을 향한 뚜렷한 추세가 나타나고 있습니다. 이러한 융합은 임상시험 설계에 혁명을 가져왔으며, 연구 후원사는 분자 시그니처를 활용하여 환자 집단을 효과적으로 계층화할 수 있을 뿐만 아니라, 치료 반응을 실시간으로 모니터링할 수도 있게 되었습니다. 이러한 혁신은 가설 검증 속도를 높일 뿐만 아니라, 적응형 프로토콜을 통해 중도 탈락률을 최소화하고 규제 당국의 신뢰를 높이는 데에도 기여합니다. 이러한 진화하는 상황은 초기 단계의 조사에서 후기 단계의 검증으로의 보다 효율적인 전환을 뒷받침하며, 궁극적으로는 경쟁 환경에서 차별화된 제품 포지셔닝을 확립하는 데 기여하고 있어, 현대 임상 조사에서 매우 중요한 요소로 자리 잡고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 오믹스 기반 임상시험 시장 규모 : 오믹스 유형별
세계의 오믹스 기반 임상시험 시장 규모 : 서비스 유형별
세계의 오믹스 기반 임상시험 시장 규모 : 단계별
세계의 오믹스 기반 임상시험 시장 규모 : 용도별
세계의 오믹스 기반 임상시험 시장 규모 : 기술별
세계의 오믹스 기반 임상시험 시장 규모 : 최종사용자별
세계의 오믹스 기반 임상시험 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.23Global Omics-Based Clinical Trials Market size was valued at USD 8.7 Billion in 2024 and is poised to grow from USD 9.81 Billion in 2025 to USD 25.72 Billion by 2033, growing at a CAGR of 12.8% during the forecast period (2026-2033).
The global market for omics-based clinical trials is experiencing significant growth driven by the rising demand for precision medicine. This approach allows for patient stratification based on molecular signatures, enhancing the effectiveness of clinical trials compared to traditional methods. Advances like next-generation sequencing have expanded analytical capabilities, enabling focused studies and improving success rates while reducing sample sizes and timelines. Regulatory frameworks are increasingly supportive of biomarker-driven research, promoting the use of multiplexed panels that can assess numerous alterations concurrently. These developments, coupled with technologies such as single-cell RNA sequencing, are streamlining trial processes, cutting costs, and attracting investment. Consequently, pharmaceutical firms are leveraging these advantages, fostering a cycle of innovation and expedited development of new therapies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Omics-Based Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Omics-Based Clinical Trials Market Segments Analysis
Global omics-based clinical trials market is segmented by omics type, service type, phase, application, technology, end user and region. Based on omics type, the market is segmented into Genomics, Proteomics, Transcriptomics, Metabolomics, Epigenomics and Multi-Omics. Based on service type, the market is segmented into Biomarker Discovery, Patient Stratification, Sample Analysis, Bioinformatics & Data Analysis, Clinical Trial Management and Others. Based on phase, the market is segmented into Phase I, Phase II, Phase III and Phase IV. Based on application, the market is segmented into Oncology, Neurology, Cardiovascular Disorders, Infectious Diseases, Rare Diseases and Others. Based on technology, the market is segmented into Next-Generation Sequencing (NGS), Mass Spectrometry, PCR Technologies, Microarrays and AI & Bioinformatics Platforms. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Omics-Based Clinical Trials Market
One key market driver for the global omics-based clinical trials market is the increasing demand for personalized medicine, which tailors treatments based on individual genetic, proteomic, or metabolic profiles. Advances in omics technologies, such as genomics, proteomics, and metabolomics, enable researchers to understand complex biological processes and identify biomarkers that can enhance the efficacy and safety of therapies. Moreover, the growing prevalence of chronic diseases and the need for more targeted therapeutic approaches are propelling investments in omics research. Consequently, pharmaceutical and biotechnology companies are increasingly adopting omics-based methodologies to streamline drug development processes and improve patient outcomes.
Restraints in the Global Omics-Based Clinical Trials Market
One of the key market restraints for the global omics-based clinical trials market is the high cost and complexity associated with integrating omics technologies into traditional clinical trial frameworks. These advanced technologies, which include genomics, proteomics, and metabolomics, require specialized equipment, skilled personnel, and significant investment in data analysis and management systems. This complexity can lead to longer trial timelines and increased operational costs, deterring smaller organizations from participating in such studies. Additionally, regulatory challenges and the need for standardization in omics data can create barriers to widespread adoption and growth in the market.
Market Trends of the Global Omics-Based Clinical Trials Market
The Global Omics-Based Clinical Trials market is experiencing a significant trend towards the integration of precision medicine, driven by advancements in omics technologies. This convergence is revolutionizing trial designs, allowing sponsors to effectively stratify patient cohorts using molecular signatures while enabling real-time monitoring of treatment responses. Such innovations not only enhance the speed of hypothesis testing but also minimize attrition rates and bolster regulatory confidence through adaptive protocols. This evolving landscape supports a more efficient transition from early-phase investigations to late-stage confirmations and ultimately aids in establishing differentiated product positioning amidst competitive therapeutic environments, making it a pivotal component of modern clinical research.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Value Chain Analysis
- Case Studies
- Technology Assessment
- Customer & Buying Criteria Analysis
- Pipeline Analysis
- Disease Epidemiology
Global Omics-Based Clinical Trials Market Size by Omics Type & CAGR (2026-2033)
- Market Overview
- Genomics
- Proteomics
- Transcriptomics
- Metabolomics
- Epigenomics
- Multi-Omics
Global Omics-Based Clinical Trials Market Size by Service Type & CAGR (2026-2033)
- Market Overview
- Biomarker Discovery
- Patient Stratification
- Sample Analysis
- Bioinformatics & Data Analysis
- Clinical Trial Management
- Others
Global Omics-Based Clinical Trials Market Size by Phase & CAGR (2026-2033)
- Market Overview
- Phase I
- Phase II
- Phase III
- Phase IV
Global Omics-Based Clinical Trials Market Size by Application & CAGR (2026-2033)
- Market Overview
- Oncology
- Neurology
- Cardiovascular Disorders
- Infectious Diseases
- Rare Diseases
- Others
Global Omics-Based Clinical Trials Market Size by Technology & CAGR (2026-2033)
- Market Overview
- Next-Generation Sequencing (NGS)
- Mass Spectrometry
- PCR Technologies
- Microarrays
- AI & Bioinformatics Platforms
Global Omics-Based Clinical Trials Market Size by End User & CAGR (2026-2033)
- Market Overview
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
Global Omics-Based Clinical Trials Market Size & CAGR (2026-2033)
- North America (Omics Type, Service Type, Phase, Application, Technology, End User)
- US
- Canada
- Europe (Omics Type, Service Type, Phase, Application, Technology, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Omics Type, Service Type, Phase, Application, Technology, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Omics Type, Service Type, Phase, Application, Technology, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Omics Type, Service Type, Phase, Application, Technology, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- IQVIA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Labcorp Drug Development
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ICON plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Parexel
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Syneos Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medpace
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tempus AI
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Illumina
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- QIAGEN
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SOPHiA GENETICS
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Natera
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Personalis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DNAnexus
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Veracyte
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Guardant Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
